SCHEMBL5887641

SCHEMBL5887641

Cc1nc(N2CCN(c3ccc(O)cc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
ALDH1A1 P00352 4/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
RXFP1 Q9HBX9 1/20 0.40
CTNNB1 P35222 1/20 0.40
TCF7L2 Q9NQB0 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MIF P14174 1/20 0.40
HTR7 P34969 2/20 0.40
POLB P06746 1/20 0.39
AURKA O14965 1/20 0.39
PPARG P37231 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886891 0.96 TP53 (0.44) MAPTTP53ALDH1A1KMT2AMEN1
SCHEMBL5887425 0.93 HTR7 (0.45) MAPTTP53ALDH1A1KMT2AMEN1
SCHEMBL5886728 0.92 CTNNB1 (0.48) MAPTTP53LMNACTNNB1TCF7L2
SCHEMBL5887548 0.91 KMT2A (0.46) MAPTTP53ALDH1A1KMT2ALMNA
SCHEMBL5886779 0.91 MAPT (0.44) MAPTTP53ALDH1A1LMNARXFP1
SCHEMBL5886747 0.91 SMN1; SMN2 (0.42) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL5886882 0.91 MAPT (0.43) MAPTTP53ALDH1A1KMT2AMEN1
SCHEMBL5886707 0.91 ALDH1A1 (0.46) MAPTTP53ALDH1A1LMNARXFP1
SCHEMBL5887306 0.90 ME2 (0.42) MAPTTP53ALDH1A1KMT2AMEN1
SCHEMBL5887104 0.90 MAPT (0.42) MAPTTP53ALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP MAPT 1614/4885TP53 43/4885ALDH1A1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.